26.5 F
New York
Wednesday, November 29, 2023

Quanterix launches LucentAD biomarker test for early Alzheimer’s disease (NASDAQ:QTRX)

Must read

Share Me


Alzheimers Disease concept , Brain degenerative diseases Parkinson


Quanterix (NASDAQ:QTRX) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer’s disease, or AD.

The diagnostics company said the test allows healthcare professionals to quickly assess the patient


Source link

- Advertisement -spot_img

More articles


Please enter your comment!
Please enter your name here

Latest article